Oncology On The Go

As part of its Between the Lines™ video series, CancerNetwork® spoke with Lyudmila Bazhenova, MD, a professor of medicine at the University of California San Diego Health, and Federico Albrecht, MD, an oncologist/hematologist at Miami Cancer Institute, Baptist Health South Florida, about when and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer (NSCLC).In the video series, Bazhenova and Albrecht discussed the following:· Presentation: Benefits and Limitations of RWE: Lessons From EGFR Mutation-Positive NSCLC · EGFR-Mutant NSCLC: Addressing Gaps When Collecting Data · Experts in Treating EGFR-Positive NSCLC Compare Randomized Trials and Real-World Studies · EGFR-Mutant NSCLC: Incorporating RWE Into Treatment Decisions · Referring to Real-World Evidence When Managing EGFR-Mutant NSCLC · Using Various Sources of Information to Guide Management of EGFR-Mutated NSCLC · Increasing Rates of Real-World Studies in EGFR-Mutated NSCLC To watch more videos in CancerNetwork®’s Between the Lines™ series, visit cancernetwork.com/between-the-lines.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork spoke with Don Dizon, MD, about certain unique challenges LGBTQ+ patients face when navigating through their cancer journey, and how providers can improve these experiences. The director of women’s cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and professor of medicine at the Warren Alpert Medical School of Brown University in Providence, touched on overcoming barriers in clinical cancer research, creating a gender-affirming environment for patients, and other important topics for treating LGBTQ+ patients with cancer.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

The final episode of CancerNetwork’s 4-part series on small cell lung cancer (SCLC) welcomes back Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. In this conversation, Iams looks to the future of SCLC treatments, touching on topics including extending response durations for patients, emerging therapies for extensive stage SCLC, exciting research on the horizon, and more.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.Check out the previous podcast episodes in this series:· Episode 1: First-Line Therapeutic Options in Small Cell Lung Cancer · Episode 2: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer · Episode 3: Practical Considerations for Small Cell Lung Cancer Therapeutic Options

Jun Gong, MD, discussed his perspective piece from the October issue of the journal ONCOLOGY, titled “An Evolving Relationship Between Medical Oncologists and Genetic Counselors in Prostate Cancer.” Gong, a practicing medical oncologist who specializes in the treatment of genitourinary cancers at Cedars-Sinai Medical Center, commented on a review article previously examined on this podcast with Alexandra Sokolova, MD, titled “Germline Testing in Prostate Cancer: When and Who to Test.”The review article focuses on the treatment implications of germline testing and how this type of testing is becoming more commonplace. Gong’s perspective applauds Sokolova and her colleagues for their work and expands on the necessary relationship between medical oncologists and genetic counselors to effectively treat patients with prostate cancer.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In the third part of a 4-part series on small cell lung cancer (SCLC), CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. The conversation focused on the toxicities of treatment options, quality of life for patients, and how Iams suggests managing and mitigating those events for individuals with SCLC. Some of the agents and regimens discussed include lurbinectedin and trilaciclib, as well as chemotherapy and immunotherapy.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.Check out the previous podcast episodes in this series:· Episode 1: First-Line Therapeutic Options in Small Cell Lung Cancer · Episode 2: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer

This week’s conversation focuses on TrialJectory, a digital health company that utilizes artificial intelligence to inform patients with cancer on their treatment journey. CancerNetwork spoke with Tzvia Bader, CEO and co-founder of TrialJectory, and Karine Perreault, who recently was diagnosed with breast cancer and is on the TrialJectory platform. The conversation touches on the perceived disconnect between the pharmaceutical industry and patients, the need to remove barriers to access testing, and the action items they thinks need to be prioritized to improve access for women with cancer.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In the second part of a 4-part series on small cell lung cancer, CancerNetwork continued its conversation with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. Iams turned the attention to different treatment options for patients with relapsed/refractory small cell lung cancer. Among others, Iams touched on lurbinectedin, topotecan, and some of the crucial clinical trials associated with treatment options for small cell lung cancer, including a phase 2 basket trial and phase 3 ATLANTIS trial examining lurbinectedin.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.Check out the first episode of this series on first-line therapeutic options in small cell lung cancer.

CancerNetwork looks at research from the October issue of the journal ONCOLOGY, titled “Value of Geriatric Assessment in Patients With Genitourinary Carcinoma.” Lead author, Quirin Zangl, MD, from the Department of Neuroanesthesia, at the Christian Doppler Hospital in Salzburg, Austria, spoke in detail about the manuscript.The research featured 111 patients with urogenital carcinomas with the goal of evaluating comprehensive geriatric assessment tools to better guide these individuals. Patients were divided into 2 groups, which were prostate cancer (n = 88) and distal urinary tract cancer (n = 29). Overall, the relationships between comprehensive geriatric assessment tools and complications, hospital duration, death rate, and baseline characteristics were analyzed.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork looks at an article from the October issue of the journal ONCOLOGY, titled “Germline Testing in Prostate Cancer: When and Who to Test.” CancerNetwork spoke with one of the authors of this article, Alexandra Sokolova, MD, an assistant professor at Oregon Health & Science University. Sokolova detailed the article, which summarizes germline testing recommendations for prostate cancer, specifically looking at the recently updated NCCN guidelines, as well as describing care models for providing counsel and testing for patients. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In this special episode of the "Oncology Peer Review On-The-Go" podcast, CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center, about therapeutic advances for small cell lung cancer. Iams discussed the current first-line therapies for small cell lung cancer, the IMpower133 and CASPIAN trials, and the factors considered for treating patients in the first-line setting. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

As part of its OncView video series, CancerNetwork spoke with Connie Batlevi, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, about recent updates in therapies for relapsed or refractory follicular lymphoma. Batlevi discussed the current treatment options for this disease, as well as third-line therapies, tazemetostat, and sequencing changes. In the video series, Batlevi discussed the following: · Current Treatment Options and Considerations for Relapsed/Refractory Follicular Lymphoma · Third-Line Therapies in R/R FL · Use of Tazemetostat in R/R FL · Sequencing Changes in R/R FL Therapies To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

This week, CancerNetwork spoke with Debra Patt, MD, PhD, MBA, FASCO, Executive Vice President at Texas Oncology. Patt discussed the rise of telehealth during the COVID-19 pandemic, how clinicians can use these tools to help treat patients with cancer, and the role of telemedicine moving forward.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of CancerNetwork’s Between the Lines video series, Brian Helfand, MD, PhD, Chief of the Division of Urology and the Ronald L. Chez Family and Richard Melman Family Endowed Chair at NorthShore University HealthSystem, and Steven Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates US Oncology Network in Panama City, Florida, examined the results and clinical implications of the phase 2/3 EMPIRE-1 trial in prostate cancer. The trial compares 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy. To watch more videos in CancerNetwork’s Between the Lines series, visit cancernetwork.com.

This episode features an examination of an article from the September issue of the journal ONCOLOGY, titled “Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification.” CancerNetwork spoke with one of the authors of this research, Jun Gong, MD, a practicing medical oncologist with an emphasis in GU cancers at Cedars-Sinai Medical Center.Gong detailed PSA’s role in prostate cancer, and other potential complementary biomarkers. He also discussed some of the significant findings from his research on plasma glutamine, which featured a cohort of over 100 patients with localized prostate cancer.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork spoke with Josh Ludwig, Global Director of Commercial Operations at ScaleReady, about how this joint venture between industry leaders launched in January, is uniquely positioned to make cell and gene therapy practical and viable. Ludwig elaborated on how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also discussed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and what’s next for ScaleReady. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork spoke with Quita Highsmith, Vice President and Chief Diversity Officer for Genentech, and Monica Baskin, PhD, a professor of preventive medicine and associate director for Community Outreach and Engagement for the O’Neal Comprehensive Cancer Center in Birmingham, Alabama. The conversation focused on the Advancing Inclusive Research Site Alliance, which is a coalition of clinical research sites partnering with Genentech to advance representation of diverse patient populations in oncology clinical trials. Results from clinical trials without diverse patient cohorts are rarely generalizable to the entire population, and this initiative works to educate and inform the clinicians and researchers to ultimately make clinical trials more accessible and eliminate these disparities. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

For the final installment of a 3-part relapsed/refractory DLBCL series, CancerNetwork heard from Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, and Kami Maddocks, MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center. These lymphoma experts spoke about their thoughts on data from the L-MIND trial, when to implement CAR-T cell therapies for patients, the role of Selinexor in treating patients, and a host of other important ideas. Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify or anywhere podcasts are available. Be sure to check out the 2 other installments of this 3-part DLBCL series on rituximab rechallenging and different treatment regimens.

As part of its OncView™ video series, CancerNetwork® spoke with Javier Munoz, MD, MS, FACP, from the Mayo Clinic in Phoenix, Arizona, about updates in therapies of relapsed/refractory follicular lymphoma.In the video series, Javier Munoz, MD, MS, FACP, discussed the following:· Current Treatment Options for Relapsed/Refractory Follicular Lymphoma · Factors in Choosing R/R FL Treatments · Treatment Options for Third-Line R/R FL · Use of Tazemetostat for R/R FL · Changes in Sequencing of R/R FL Therapies To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

As part of its OncView™ video series, CancerNetwork® spoke with Lee Schwartzberg, MD, FACP, of the West Cancer Center and Research Institute in Germantown, Tennessee, about updates to the National Comprehensive Cancer Network (NCCN) guidelines regarding hormone receptor (HR)–positive breast cancer.In the video series, Lee Schwartzberg, MD, FACP, discussed the following:· Extended Adjuvant Therapy for HR+ Breast Cancer · Molecular Biomarkers for HR+ Breast Cancer · Role of Genomic Testing in HR Positive Breast Cancer · Appropriateness for Genomic Testing in HR+ Breast Cancer · Integration of Genomic Testing into NCCN Guidelines · Current Recommendations for Genomic Testing in HR+ Breast Cancer · Treatment Limitations in HR+ Breast Cancer To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week's podcast focuses on a review article published in the June issue of the journal ONCOLOGY titled, “Routine Breast Cancer Screening in Average-Risk Women Younger Than 50 Years: Current Paradigms Based on National Guidelines.” CancerNetwork spoke with Anath Ravi, PhD, co-founder and chief science and clinical officer of MOLLI Surgical, and Randy Miles, MD, MPH, an assistant professor in the Department of Radiology and clinical service chief in the Division of Breast Imaging at Massachusetts General Hospital, about their work with breast cancer screenings for women under the age of 50.The conversation focused on the current breast cancer screening guidelines, the risks and benefits of screening for women between the ages of 40 and 49, the different imaging techniques and what roles they play, as well as the future direction of breast cancer screening.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork review an article published in the July issue of the journal ONCOLOGY titled, “Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies.” CancerNetwork spoke with Thejaswi Poonacha, MD, MBA, a staff physician and hospitalist in the department of internal medicine at the University of Minnesota Medical Center, regarding the research from him and his colleagues. The conversation focused on the scientific evidence behind the NCCN guidelines for hematologic malignancies, how each category corresponds with different levels of evidence, and the main findings from this study. Poonacha shared exactly what this means, and why this research was so significant for this group of authors. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork spoke with Kami Maddocks MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University, about CD-19 directed agents, avoiding rechallenging with rituximab, and second-line outcomes for transplant-ineligible patients with diffuse large B-cell lymphoma (DLBCL). Visit cancernetwork.com to check out the first episode of this 3-part series here. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork® examined an article from the June issue of the journal ONCOLOGY® titled “Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell Cancer” by speaking with one of the authors, Robert A. Figlin, MD. Figlin, who is a professor of medicine and biomedical sciences, Steven Spielberg Family Chair in Hematology-Oncology, and deputy director of Cedars-Sinai Cancer at the Cedars-Sinai Medical Center in Los Angeles, California, spoke about the evolving treatment paradigm of metastatic clear cell renal cell carcinoma, specifically how the shifting landscape of first-line therapies has impacted second-line therapeutic strategies. He discussed standard therapeutic strategies in this space, such as the use of immunotherapy and tyrosine kinase inhibitors, and how new data affect where these agents fit in to patient care. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with Benjamin Levy, MD, of the John Hopkins Sidney Kimmel Comprehensive Cancer Center, to discuss frontline management of extensive-stage small cell lung cancer (SCLC) and the recent updates in the field. In the video series, Levy discussed the following: · Small Cell Lung Cancer: Risk and Prognosis · Small Cell Lung Cancer: Standard of Care · Extensive-Stage Small Cell Lung Cancer: Gaps in Treatment · Immunotherapy for First-Line Extensive-Stage SCLC · First-Line I-O Plus Chemotherapy for Extensive-Stage SCLC · Significance of the IMpower133 Trial in Extensive-Stage SCLC To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your podcasts.

In this episode, CancerNetwork spoke with 2 experts on the topic of biosimilars, Howard Hochster, MD, FACP, Associate Director for Clinical Research at the Rutgers Cancer Institute of New Jersey and Distinguished Professor of Medicine at the Rutgers School of Medicine, and Michael Kane, RPh, BCOP, Executive Director of Oncology Pharmacy Services for RWJBarnabas Health and Director of Pharmacy Services and the Research Pharmacy at the Rutgers Cancer Institute of New Jersey.The episode dives into the background of biosimilars, including the Biologics Price Competition and Innovation Act (BPCIA) passed by the United States Congress in 2009 and subsequent 4-letter suffix rule used to identify biologics products without confusion. The conversation also analyzed some of the unintended consequences of these actions regarding biosimilars, and what Hochster and Kane would do to improve the system that’s currently in place.

In this episode, CancerNetwork spoke with Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, about recently approved and emerging treatment regimens for transplant-ineligible diffuse large B-cell lymphoma (DLBCL). Salles discussed some of the available treatment options including tafasitamab, CAR T-cell therapies, selinexor, and antibody drug conjugates (ADCs). He also looked ahead at some of the upcoming research on the horizon, including the B-MIND trial investigating tafasitamab or rituximab plus bendamustine.

As part of the OncView video series, CancerNetwork spoke with Mark Socinski, MD, of the AdventHealth Cancer Institute in Orlando, Florida about updates in the management of extensive-stage small cell lung cancer (ES-SCLC). Socinski touched on a number of important aspects of treating this disease, including the existing standards of care, treatment challenges, immunotherapy, IMpower 133 trial, and more. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your podcasts.

This week, "Oncology Peer Review On-The-Go" discussed an article from the May issue of the journal ONCOLOGY titled “Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community Physicians.” CancerNetwork spoke with Christine Chung, DO, from the HCA Swedish Medical Center in Englewood, Colorado, about the molecular profiling patterns she and her colleagues observed in this retrospective review. The authors found that both academic and community physicians ordered profiling about 50% of the time, which was contrary to previous reports that suggest academic centers perform molecular profiling more often. The perspective for this article comes from Roman Groisberg, MD, a medical oncologist and director of the Sarcoma Medical Oncology Program at the Rutgers Cancer Institute. Groisberg discussed the role of profiling in pancreatic adenocarcinoma, his thoughts on the retrospective review, and the future of profiling for this cohort of patients. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with Sameh Gaballa, MD, of the Moffit Cancer Center, about current and future treatment options, and considerations for patients with relapsed/refractory follicular lymphoma. In the video series, Gaballa discussed the following:· Treatment Options in Relapsed/Refractory Follicular Lymphoma · Considerations for Treatment Selection in R/R FL · Third-Line Therapy in Follicular Lymphoma · Tazemetostat for Relapsed/Refractory Follicular Lymphoma · R/R FL: The Role of PI3K Inhibitors · Unmet Needs and Looking Ahead in Follicular Lymphoma To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

The May issue of the journal ONCOLOGY featured a review article titled “Primary Focal Therapy for Localized Prostate Cancer: A Review of the Literature.” Sudhir Isharwal, MD, an assistant professor in the Department of Urology at Oregon Health & Science University in Portland, Oregon, discussed the emergence of focal therapies in the last few years for the treatment of patients with localized prostate cancer. This literature review investigated some of the advantages and drawbacks of various therapeutic models in this space. The perspective for this article was written by Thomas Polascik, MD, a professor of Surgery/Urology and director of Focal Therapy at the Duke Cancer Center, Duke Medical Center in Durham, North Carolina. Polascik discussed the response he wrote to this article, titled “Prostate Cancer Focal Therapy Has Made Great Strides and the Future Remains Bright.” He touched on all aspects of focal therapy, including history, potential hurdles, and patient selection and surveillance, among other things. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

The feature article for this episode comes from the April issue of the Journal ONCOLOGY titled “Treatment Considerations for Transplant-Ineligible Multiple Myeloma.” Sarah Holstein, MD, an associate professor of internal medicine in the Division of Oncology & Hematology at University of Nebraska Medical Center in Omaha, Nebraska, spoke about the need for further research into treatment options for the older and more frail patient population of multiple myeloma.Holstein also explained the importance of understanding results from multiple myeloma clinical trials through the lens of how they apply to this specific transplant-ineligible population. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

As part of its OncView video series, CancerNetwork spoke with Reshma L. Mahtani, DO, Sylvester Comprehensive Cancer Center, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting. In the video series, Gadi discussed the following: · Extended Adjuvant Therapy for HR+ Breast Cancer · NCCN Updates to Genomic Testing in HR+ Breast Cancer · Genomic Testing for HR+ Breast Cancer: Best Practices · Utilization of The Breast Cancer Index for HR+ Breast Cancer · Optimizing Treatment Outcomes in HR+ Breast Cancer To watch more videos in CancerNetwork’s OncView series, visit cancernetwork.com.

As part of its OncView video series, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD, University of Illinois College of Medicine, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting. In the video series, Gadi discussed the following: · Adjuvant Vs Extended Adjuvant Therapy in HR+ Breast Cancer · Predictive and Prognostic Factors in HR+ Breast Cancer · Role of Genomic Testing in HR+ Breast Cancer · NCCN Guideline Updates for the Use of Genomic Assays in HR+ Breast Cancer · Identifying Patients for Extended Adjuvant Therapy With the Breast Cancer Index in HR+ Breast Cancer · Improving the Management of HR+ Breast Cancer: Next Steps To watch more videos in CancerNetwork’s OncView series, visit cancernetwork.com.

This episode features an article published in the April issue of the Journal ONCOLOGY titled “Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer.” The lead author of the research, E. David Crawford, MD, a urologic oncologist, and professor of urology at the University of California San Diego, explained their research into prostate cancer disease states. Among other things, Crawford and the research team talked about next-generation imaging, biomarkers, and redefined prostate cancer disease states to introduce transitional disease into that equation.The response perspective for this article comes from Rana McKay, MD, an associate professor of medicine and urology at the University of California San Diego. McKay provided some of her thoughts on the idea of redefining prostate cancer disease states and really emphasized the need for clinical research to validate treatment options and current practices.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This episode features an article published in the Journal ONCOLOGY titled “Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.”CancerNetwork spoke with the corresponding author, Jun Gong, a medical oncologist at Cedars-Sinai Medical Center, to discuss the 4 PARP inhibitors that have undergone significant investigation for the treatment of patients with metastatic castrate-resistant prostate cancer. While elaborating on these PARP inhibitors, Gong also discussed the importance and potential value of successfully integrating these agents into prostate cancer practice.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In this episode, CancerNetwork sat down for a conversation with David Johnson, chairman and CEO of Enveric Biosciences. Johnson gave a thorough background of the biosciences company, and detailed the endocannabinoid products Enveric is developing to positively impact the quality of life for patients with glioblastoma.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast anywhere podcasts are available.

This episode of the "Oncology Peer Review On-The-Go" podcast centers around an article publishing in the April issue of the Journal ONCOLOGY, titled “Messenger RNA Vaccines-Beckoning of a New Era in Cancer Immunotherapy.” The article touches on the recent development of mRNA vaccines approved to combat COVID-19, and how this development offers optimism for the future of mRNA to treat patients with cancer. The author, Mehmet Sitki Copur, MD, of the University of Nebraska Medical Center, broke down the basics of mRNA, its history, challenges and potential opportunities around this relatively new class of vaccine.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In this episode, CancerNetwork examines an article from the March issue of the Journal ONCOLOGY titled “Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer.” The original research article found that treatment refusal among patients with small cell lung cancer was associated with worse survival, and strategies to increase patient acceptance of the recommended treatment need to be studied further. CancerNetwork spoke with one of the authors, KM Monirul Islam, MD, of the Georgia Medical Center, to learn more about this research. For the response perspective, CancerNetwork spoke with Jennifer Carlisle, MD, an assistant professor of hematology and medical oncology at Winship Cancer Institute of Emory University. Carlisle spoke about small cell lung cancer, how treatment refusal impacts treatment of a patient, and plenty more regarding this original research.

This week, CancerNetwork sat down for a 1-on-1 conversation with former Chief Medical Officer and Executive Vice President of ASCO, Richard Schilsky, MD, to discuss ASCO’s 2021 "Advance of the Year," molecular profiling driving progress in gastrointestinal cancers. Schilsky discussed the progress being made in this field and the top research contributing to the momentum in gastrointestinal cancers, while also elaborating on health equity in cancer research, ASCO’s top research priorities moving forward, and more.He also explained the changes forced on clinical trials due to the coronavirus disease 2019 (COVID-19) pandemic, and how he anticipates trials can leverage these adjustments moving forward in a post-COVID world.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork examined a review article published in the February issue of the Journal ONCOLOGY titled “Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.” The piece highlights the existing literature regarding the prognostic and predictive capabilities of the 21-gene recurrence score in patients with node-positive breast cancer, focusing on current practice patterns and emerging applications from the surrounding literature. For the summary, CancerNetwork spoke with 2 authors of the review, Alison Laws, MD, an associate surgeon at the Brigham and Women’s Hospital and Philip Poorvu, MD, a medical oncologist at the Dana Farber Cancer Institute. Laws and Poorvu provided valuable information on the process, focus and main takeaways of this review. For the article’s response perspective, CancerNetwork spoke with Sara Hurvitz, MD, a professor of medicine at the UCLA Johnson Comprehensive Cancer Center. Hurvitz detailed a number of studies analyzed by the review article, putting into perspective the findings from various pieces of literature. She expanded on the team’s work, and looked toward the future for treating patients with node-positive breast cancer. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork spoke with Justin Gregg, MD, about a study published in Cancer titled “Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort.” Gregg, an assistant professor of urology at The University of Texas MD Anderson Cancer Center and the lead author of the study, explained that the Mediterranean diet was associated with a lower risk of Gleason Grade group progression among men with localized prostate cancer on active surveillance. Larger follow-up studies are still necessary to verify the patient- and cancer-specific effects of adherence to the Mediterranean diet.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In this episode, CancerNetwork speaks with Ashwatha Narayana, MD, a professor and chairman of radiation oncology at Northern West Chester Hospital. Narayana co-authored a review article titled “Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation Therapy and Conventional Fractionation.” The article published in the January issue of the Journal ONCOLOGY and discusses the surrounding literature regarding palliative radiation therapy for spinal metastases. More, the team provides recommendations algorithmically to best select patients with metastatic disease for palliative spinal SBRT.

In the first episode of 2021, CancerNetwork spoke with Che-Kai Tsao, MD, a medical oncologist at Mount Sinai. Tsao discussed smoking cessation, its relation to cancer, and screenings for patients. More, he went into detail regarding the National Cancer Institute-funded smoking cessation program, a program Mount Sinai has been a part of for a number of years. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In this episode of "Oncology Peer Review On-The-Go", CancerNetwork takes a look at an article publishing in early 2021 for the Journal ONCOLOGY, titled “Patient-Reported Outcomes of Pain and Related Symptoms in Integrative Oncology Practice and Clinical Research: Evidence and Recommendations.”The piece summarizes current and validated patient-reported outcomes (PROs) specific to cancer-related pain. The piece also recommends commonly used PROs to be standardized to aid integrative oncology clinicians and researchers in both patient care and study design. For the first of 2 interviews regarding this piece, CancerNetwork spoke with 3 authors of the article, W. Iris Zhi, MD, PhD, and Ting Bao, MD, DABMA, MS, from the Memorial Sloan Kettering Cancer Center, and Xin Shelley Wang, MD, MPH, of the MD Anderson Cancer Center. For this week’s response perspective, CancerNetwork spoke with Linda Carlson, PhD, of the Cumming School of Medicine at the University of Calgary. Carlson expanded on the work done by Zhi and her colleagues, emphasizing the importance of understanding reliability and validity. Carlson focused on the importance of the research topic, and the impact properly validated PROs can have on patients for the cancer care team.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In this edition of "Oncology Peer Review On-The-Go," CancerNetwork spoke with Zuri Murrell, MD, for a conversation regarding the rising rates of colorectal cancer for younger individuals, as well as the significantly higher incidence and death rates for black patients of this cancer type. Murrell, a colorectal surgeon and cancer specialist at Cedars-Sinai, explained that obesity, diabetes, smoking, and a family history of colorectal cancer may all play a role in the increasing rate. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available .

This latest episode of "Oncology Peer Review On-The-Go" looks at an article published in the November issue of the journal ONCOLOGY, titled “Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women With Cancer.” The piece examines oncofertility, unexpected cancer diagnoses and the decision-making process for young adult patients. For a breakdown of the article, CancerNetwork spoke with co-author of the review article, Jackelyn Payne, MPH, MA, a doctoral student in the department of psychology at Stony Brook University. For the response perspective, CancerNetwork spoke with Elizabeth Constance, MD, who is an associate professor at the University of Nebraska Medical Center. Constance wrote a perspective piece published in the journal ONCOLOGY titled “Opening Doors: Fertility Preservation for Adolescents and Young Adults Facing Gonadotoxic Therapy.” The piece highlights the evolving decision-making process for patients, the potential for multi-disciplinary treatment teams and more. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This episode of "Oncology Peer Review On-The-Go" examines an article published in the October issue of the journal ONCOLOGY, titled “Barriers to Clinical Trial Enrollment in Patients With Pancreatic Adenocarcinoma Who Are Eligible for Early-Phase Clinical Trials.” The piece was written by Rachael Galvin, DO, MPH, Christine Chung, DO, Ella Achenbach, Oliwier Dziadkowiec, PhD, and Shiraj Sen, MD, PhD, and focuses on what keeps patients of this aggressive form of pancreatic cancer from pursuing enrollment in clinical trials. For a summary of the article, CancerNetwork spoke with lead author of the study, Rachael Galvin, DO, MPH, from the Swedish Medical Center in Englewood, Colorado. For the article’s response perspective, CancerNetwork spoke with Michael Lee, MD, of the MD Anderson Cancer Center. Lee discussed his perspective piece published on CancerNetwork titled “Barriers to Pancreatic Cancer Clinical Trials Enrollment.” The piece examines Galvin’s work and clinical trial enrollment for the disease as a whole. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This episode of “Oncology Peer Review On-The-Go” examines an article published in the October issue of the journal ONCOLOGY, titled “Considerations for the Management of Oncology Patients During the COVID-19 Pandemic.” The piece focuses on the management of the coronavirus pandemic and best practices to effectively manage patients with cancer. For detailed information regarding the article, CancerNetwork spoke with two authors of the study, Jeffrey Schneider, MD, and Marc Braunstein, MD, PhD, from the NYU Winthrop Hospital. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This episode of "Oncology Peer Review On-The-Go" features an article published in the September issue of the journal ONCOLOGY. The article is titled “Screening for Phase 1 Clinical Trials: An Opportunity to Evaluate Psychological States and Re-educate Patients on Prognosis?” It was written by Sarah Moreland, MD, and Shiraj Sen, MD, PhD, and focuses on physician-patient communication and the psychosocial impact of cancer diagnoses on patients. For more information regarding the article, CancerNetwork spoke with Dr. Moreland from the Medical Center of Aurora. For the article’s response perspective, CancerNetwork spoke with Daniel McFarland, DO, of the Memorial Sloan Kettering Cancer Center about the physician-patient relationship and the importance of clear communication throughout the clinical trial process.

This episode of "Oncology Peer Review On-The-Go" examines a review article published in the September issue of the journal ONCOLOGY. The article, “Molecular Profiling in Metastatic Colorectal Cancer,” was written by Samantha Armstrong, MD, Rita Malley, MS, and Benjamin Weinberg, MD. The piece discusses the epidemiology, tumor location, and mutational landscape of metastatic colorectal cancer. For an in-depth evaluation of that piece, CancerNetwork spoke with Armstrong and Weinberg from the Georgetown Lombardi Comprehensive Cancer Center. For the article’s response perspective, CancerNetwork spoke with John Marshall, MD, of the Georgetown Lombardi Comprehensive Cancer Center. Dr. Marshall discussed the cost, quality of care, accessibility and more regarding molecular profiling and precision medicine. Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify or anywhere podcasts are available.